Analysis Tools
digestive/alimentary system
| N |
• untreated mice are healthy and exhibit normal intestine histology
|
|
• DSS-treated mice show a trend towards a decrease in Ki-67-positive proliferating intestinal epithelial cells in colon crypts
|
|
• DSS-treated mice show a complete loss of crypts in a wide area of the distal colon with a 65.1% rate of crypt damage versus 33.4% in wild-type controls
|
|
• DSS-treated mice show a reduction in colon goblet cell number
|
|
• DSS-treated mice show diffuse ulcers in the distal colon
|
|
• vehicle-treated mice exhibit significantly lower mRNA levels of Wnt5a in the colon than vehicle-treated wild-type controls, suggesting a potential loss of tissue repair capacity
• decreased expression of Tgfb1 upon DSS treatment may lead to decreased TGF-beta pathway-dependent WNT5A-mediated colonic crypt repair and exacerbated crypt loss
|
|
• dextran sulfate sodium (DSS)-treated male mice exhibit exacerbated colitis with higher Disease activity index (DAI) scores than DSS-treated wild-type controls after day 5; significant weight loss on day 5 with a 17.5% weight loss by day 7; loose stools, diarrhea and bloody stools on day 6; more extensive pathological changes (goblet cell reduction, diffuse ulcers); and a complete loss of crypts in a wide area of the distal colon with a 65.1% rate of crypt damage versus 33.4% in wild-type controls
|
immune system
|
• dextran sulfate sodium (DSS)-treated male mice exhibit exacerbated colitis with higher Disease activity index (DAI) scores than DSS-treated wild-type controls after day 5; significant weight loss on day 5 with a 17.5% weight loss by day 7; loose stools, diarrhea and bloody stools on day 6; more extensive pathological changes (goblet cell reduction, diffuse ulcers); and a complete loss of crypts in a wide area of the distal colon with a 65.1% rate of crypt damage versus 33.4% in wild-type controls
|
|
• vehicle-treated mice exhibit significantly lower mRNA levels of Il10 (interleukin 10) in the colon than vehicle-treated wild-type controls, with no further downregulation of Il10 in response to DSS treatment
|
endocrine/exocrine glands
|
• DSS-treated mice show a complete loss of crypts in a wide area of the distal colon with a 65.1% rate of crypt damage versus 33.4% in wild-type controls
|
|
• DSS-treated mice show a reduction in colon goblet cell number
|
homeostasis/metabolism
|
• vehicle-treated mice exhibit significantly lower mRNA levels of Il10 (interleukin 10) in the colon than vehicle-treated wild-type controls, with no further downregulation of Il10 in response to DSS treatment
|
|
• mRNA levels of Tgfb1, an anti-inflammatory cytokine, are significantly reduced in the colon relative to wild-type controls regardless of DSS treatment
|
growth/size/body
|
• DSS-treated mice exhibit marked weight loss starting on day 5 with a 17.5% weight loss noted by day 7, unlike DSS-treated wild-type controls which show no significant body weight changes
|
cellular
|
• DSS-treated mice show a reduction in colon goblet cell number
|
|
• DSS-treated mice show a trend towards a decrease in Ki-67-positive proliferating intestinal epithelial cells in colon crypts
|
